A Research Guide for
Facing Non-Hodgkin Lymphoma

Across all NHL subtypes combined, approximately 7 out of 10 people in the United States are alive five years after diagnosis. For many subtypes the number is considerably higher:

• DLBCL (the most common aggressive NHL): Approximately 60 to 70 percent of patients are cured with first-line treatment.
• Follicular lymphoma: Patients often live 15 to 20+ years. Published long-term data suggest roughly 40 percent of patients on chemoimmunotherapy may achieve what appears to be cure.
• Gastric MALT lymphoma: Often cured by antibiotics alone when driven by H. pylori infection.
• Ocular adnexal MALT: Often controlled for many years with doxycycline when driven by Chlamydia psittaci infection.
• Primary CNS lymphoma in younger patients: Five-year survival is now around 50 to 70 percent with modern protocols.

Some subtypes remain challenging. Double-hit and triple-hit DLBCL, relapsed peripheral T-cell lymphoma (PTCL), transformed follicular lymphoma, adult T-cell leukemia/lymphoma (ATLL), and primary CNS lymphoma in older adults all still have lower cure rates. For these, standard chemotherapy alone is often not enough. This is exactly where the layered approach in this guide — molecular testing, careful supportive care, metabolic timing around immunotherapy, and access to international protocols — may matter the most.

NHL treatment has changed more in the last five years than in the previous twenty. Three developments are driving this:

• Genetic subtyping. Clinicians can now read the DNA inside the lymphoma cell. Different genetic patterns respond to different drugs. This underlies the precision-medicine approach described later in this guide.
• Cellular and bispecific therapies. CAR T-cells (the patient’s own immune cells, re-engineered to target lymphoma), bispecific antibodies, and engineered NK cells now produce durable remissions in many patients who would have had limited options a decade ago.
• Metabolism and immunity. Published research now demonstrates that diet, fasting, ketone levels, and certain inexpensive older medications may influence how lymphoma cells survive and how immune cells function. This area is evolving rapidly.

Treatment: Standard triple antibiotic therapy (proton pump inhibitor + two antibiotics, typically amoxicillin and clarithromycin) for 10–14 days.

Published outcomes: Antibiotic treatment alone results in lymphoma regression in up to 75% of early-stage gastric MALT cases, often without chemotherapy. If H. pylori is negative or the lymphoma persists after eradication, low-dose radiation to the stomach is considered curative for most patients.

Treatment: Direct-acting antiviral pills for 8–12 weeks (sofosbuvir-based regimens).

Published outcomes: Many indolent lymphomas regress when HCV is cleared.

Treatment: Antiviral prophylaxis (entecavir or tenofovir) before and during rituximab therapy.

Why this matters: HBV reactivation during rituximab can be life-threatening. Both HBsAg and HBcAb must be tested — core antibody positivity alone indicates risk.

Treatment: Arsenic trioxide + interferon-alpha + zidovudine (AZT) targets the viral oncoprotein. This is distinct from chemotherapy.

Published outcomes: Phase 2 trials in chronic and smoldering ATLL have reported durable responses, with some patients alive beyond 5 years.

Testing: Recommended for patients of Caribbean, Japanese, or West African ancestry, or any patient with T-cell lymphoma.

Treatment: Doxycycline 100 mg twice daily for 3–6 weeks.

Published outcomes: In published series, approximately 75% of patients achieved 2-year progression-free survival. Some series report median PFS extending beyond 14 years. If response is inadequate, low-dose radiation is used.

EBV: Drives a distinct biology in some PTCL, ENKTL, and post-transplant lymphomas. No direct cure; EBV-specific T-cells are experimental. Influences treatment choice.

HIV: Modern antiretroviral therapy combined with chemoimmunotherapy has made outcomes for AIDS-related NHL nearly comparable to HIV-negative patients.

The most common aggressive NHL. Standard first-line is R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone), given every 21 days for 6 cycles.

• Higher-risk DLBCL (IPI ≥ 2): Pola-R-CHP (polatuzumab vedotin replaces vincristine) is now preferred based on the POLARIX trial, which demonstrated improved progression-free survival.
• Double-hit / triple-hit DLBCL: DA-EPOCH-R (dose-adjusted etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin + rituximab) is the more intensive option typically recommended.
• Double-expressor DLBCL (MYC and BCL2 protein both high, without FISH rearrangement): Published phase 3 trial data (DEB trial, NCT04231448) showed that adding tucidinostat (chidamide) to R-CHOP reduced the risk of progression or death by 28% and improved complete response from approximately 62% to 73%. Access outside China may require a clinical trial or compassionate-use application — see the International Approaches section.

Estimated costs: R-CHOP is widely available; rituximab biosimilars have reduced costs. Pola-R-CHP adds the cost of polatuzumab vedotin (~$14,000–$18,000 per cycle before insurance). Most insurance plans cover standard regimens. Financial assistance is available through the Leukemia & Lymphoma Society (800-955-4572).

FL is usually indolent (slow-growing). Most patients live for many years.

• Watch and wait: For asymptomatic, low-burden disease. Well-studied and safe in selected patients.
• When treatment is needed: Bendamustine + rituximab (BR) or R-CHOP, then rituximab maintenance every two months for two years.
• Relapsed FL: Lenalidomide + rituximab (“R-squared”); CAR-T (axicabtagene ciloleucel per ZUMA-5 — published long-term data at 5+ years show 90% overall response, 75% complete response); bispecific antibodies (mosunetuzumab, glofitamab); tazemetostat (if EZH2-mutated).

MCL behaves between indolent and aggressive. Most patients need treatment soon after diagnosis.

• First-line (fit, under 65): Intensive chemo (Nordic protocol or alternating R-CHOP / R-DHAP) followed by autologous stem cell transplant.
• First-line (older patients): BR or VR-CAP (with bortezomib), then rituximab maintenance.
• Relapsed MCL: BTK inhibitors (acalabrutinib, zanubrutinib, pirtobrutinib), venetoclax combinations, brexucabtagene autoleucel (Tecartus) CAR-T.
• NEW in 2026 — Sonrotoclax (Beqalzi): Next-generation BCL-2 inhibitor. FDA accelerated approval May 13, 2026 for relapsed/refractory MCL after ≥2 prior treatments including a BTK inhibitor. In the BGB-11417-201 trial: 52% overall response, median time to response 1.9 months, median duration of response 15.8 months. Requires a 4-week dose ramp-up (to reduce tumor lysis syndrome risk), then 320 mg orally once daily.
• Durable remissions with venetoclax + ibrutinib: AIM trial 7-year follow-up reported that 10 of 17 MRD-negative complete responders stayed in treatment-free remission for a median of 58 months.

Three types: extranodal MALT, nodal MZL, and splenic MZL.

• Gastric MALT: Treat H. pylori first. If H. pylori-negative or lymphoma persists, low-dose radiation is curative for most.
• Ocular adnexal MALT: Doxycycline 100 mg twice daily for 3 weeks. If response inadequate, low-dose radiation.
• Splenic MZL: Treat HCV if present. Otherwise rituximab alone, or splenectomy in selected cases.
• Other MZL: Rituximab-based regimens. Zanubrutinib is FDA-approved for relapsed MZL.

A challenging family of diseases. Standard CHOP alone is often insufficient, and adding novel agents matters significantly.

• CD30-positive PTCL: Brentuximab vedotin + CHP (BV-CHP). For ALK-positive ALCL, this has been transformative.
• CD30-negative PTCL: CHOEP, followed by autologous stem cell transplant in first remission for eligible patients.
• Relapsed PTCL: Pralatrexate, romidepsin, belinostat, tucidinostat (approved in China for relapsed PTCL), CAR-T trials.

Rare in Western countries, more common in Asia and Latin America. EBV-driven and aggressive.

• Early stage (I/II): Radiation plus L-asparaginase-based chemotherapy.
• Advanced stage (III/IV): DDGP (dexamethasone + cisplatin + gemcitabine + pegaspargase) outperformed the older SMILE regimen in a randomized trial (NCT01501149). Published 5-year overall survival was 74% with DDGP vs. 52% with SMILE. DDGP is now the preferred backbone.
• Relapsed ENKTL: PD-1 inhibitor + tucidinostat combinations have shown high response rates in published Chinese trials.

• Early skin-only stages: Topical steroids, topical mechlorethamine gel, narrow-band UVB or PUVA phototherapy, localized radiation.
• Advanced or systemic: Bexarotene, interferon-alpha, extracorporeal photopheresis, romidepsin, vorinostat, brentuximab vedotin (if CD30-positive).
• Mogamulizumab (Poteligeo): FDA-approved for relapsed/refractory mycosis fungoides and Sézary syndrome. Published registry data (PROCLIPI) report median overall survival of 64 months on mogamulizumab vs. 54 months without it. Available at any U.S. oncology infusion center; insurance approval typically takes 2–4 weeks.

Caused by HTLV-1. Most common in Japan, the Caribbean, parts of West Africa, and South America.

• Chronic/smoldering ATLL: Arsenic trioxide + interferon-alpha + zidovudine (AZT). Targets the Tax viral oncoprotein. Published data report durable responses with some patients alive beyond 5 years.
• Aggressive acute ATLL: Combination chemotherapy (modified EPOCH or VCAP-AMP-VECP), often followed by allogeneic stem cell transplant. Mogamulizumab is also active.

Lymphoma confined to the brain, spinal cord, or eyes. Modern outcomes have improved significantly in younger patients.

• Induction: High-dose methotrexate-based combinations (MATRix protocol: methotrexate + cytarabine + thiotepa + rituximab).
• Consolidation: Autologous stem cell transplant with thiotepa-based conditioning, or whole-brain radiation in patients who cannot have transplant.
• Relapsed PCNSL: Ibrutinib (especially for MYD88-mutated — most cases), lenalidomide + rituximab, temozolomide + rituximab, CAR-T trials.

Same disease in blood (CLL) vs. lymph nodes (SLL). Often indolent.

• First-line: BTK inhibitor (acalabrutinib or zanubrutinib preferred — fewer cardiac side effects than ibrutinib) given continuously, or venetoclax + obinutuzumab as time-limited therapy.
• Watch and wait: Correct for asymptomatic early-stage CLL.
• Note on statins in CLL: A published pooled analysis of 4 randomized trials (1,467 CLL/SLL patients on ibrutinib) found markedly lower mortality (adjusted HR 0.62) and longer progression-free survival in statin users. Statins do not replace CLL treatment, but if you have a cardiovascular reason to be on one, discuss this with your team.

Epigallocatechin gallate (EGCG) is the principal polyphenol in green tea. A standardized pharmaceutical-grade preparation called Polyphenon E has been studied specifically in early-stage CLL patients who are on watch-and-wait (not yet requiring treatment).

• Mayo Clinic Phase II trial: Polyphenon E (standardized EGCG extract) was given to early-stage CLL patients on observation. The study reported a decline in absolute lymphocyte count (ALC) in a meaningful proportion of participants, with some patients experiencing sustained reductions in lymph node size.
• Mechanism: EGCG has been shown in laboratory studies to induce apoptosis in CLL cells through inhibition of VEGF receptor signaling, downregulation of Mcl-1 and XIAP, and activation of caspase pathways. It also modulates Bcl-2 family proteins.
• What this means: This is early evidence suggesting EGCG may have modest biological activity against CLL cells. For patients who are on watch-and-wait and looking for evidence-based supportive measures, pharmaceutical-grade EGCG is a reasonable discussion with the hematologist.

Practical notes: Over-the-counter green tea extracts vary widely in EGCG content and quality. The clinical studies used pharmaceutical-grade Polyphenon E at specific doses. If pursuing this, use third-party tested products and start at lower doses with liver function monitoring. Drinking green tea in normal amounts (3–5 cups/day) provides a much lower EGCG dose and is generally safe.

Burkitt: Extremely fast-growing. Treated with intensive multi-drug regimens (R-EPOCH or R-CODOX-M/IVAC). High cure rates in younger patients (>80%). Treatment should start within days. Tumor lysis syndrome is the main acute danger — requires aggressive hydration and monitoring.

Hairy Cell Leukemia: Rare. Cladribine or pentostatin produces long remissions in most patients. BRAF V600E mutation is nearly always present; vemurafenib is used in relapsed cases.

• Morphology / histology: How the cells look under a microscope. This gives the basic subtype name (e.g., diffuse large B-cell, follicular, mantle cell). “Diffuse” means the abnormal cells are spread throughout the tissue; “follicular” means they form clusters resembling normal lymph node follicles.
• Immunohistochemistry (IHC): Stains that identify proteins on cell surfaces. Common markers: CD20 (most B-cell lymphomas), CD3/CD5 (T-cell), CD10, BCL2, BCL6, MUM1 (help classify DLBCL as germinal center or non-germinal center origin), Ki-67 (shows how fast cells are dividing — higher % = more aggressive).
• Cell of origin (COO): For DLBCL, this is critical. “Germinal center B-cell (GCB)” type has a better prognosis than “activated B-cell (ABC)” type. Determined by gene expression profiling (preferred) or the Hans algorithm (IHC-based approximation).
• FISH (fluorescence in situ hybridization): Detects chromosomal rearrangements. The key ones: MYC, BCL2, BCL6. A “double-hit” lymphoma has rearrangements in both MYC and BCL2 (or BCL6) and requires more intensive treatment.
• Grade: For follicular lymphoma: Grade 1–2 = indolent, Grade 3A = borderline, Grade 3B = treated as aggressive. For other subtypes, grading criteria vary.
• Ki-67 proliferation index: Percentage of cells actively dividing. Higher Ki-67 generally means more aggressive. In mantle cell lymphoma, Ki-67 ≥30% is an adverse prognostic factor.
• Flow cytometry: Tests performed on fresh tissue or blood to identify cell surface markers quickly. Often confirms the subtype alongside IHC.
• NGS (next-generation sequencing): Identifies specific gene mutations that may affect treatment choice (e.g., EZH2 mutations in follicular lymphoma, TP53 mutations in various subtypes).

What to do with your report: Ask your oncologist to walk through it with you. If anything is unclear or incomplete (especially FISH and cell of origin in DLBCL), request the additional testing before treatment begins. A second pathology review at a high-volume lymphoma center is reasonable for any NHL diagnosis.

The Shanghai Protocol (Genetic-Subtype-Guided R-CHOP-X)

Developed at Ruijin Hospital and other major Chinese centers, this approach matches the DNA changes inside a DLBCL to a specific added drug (“X”). In the published randomized phase 2 GUIDANCE-01 trial in newly diagnosed intermediate-to-high-risk DLBCL, this approach showed markedly higher response rates compared to standard R-CHOP. The follow-up GUIDANCE-06 trial extended the approach to relapsed/refractory DLBCL.

How to use this: Ask your oncologist whether your NGS report assigns your DLBCL to a LymphGen-style genetic subtype, and search ClinicalTrials.gov for subtype-targeted trials.

Tucidinostat (Chidamide) — China’s HDAC Inhibitor

An oral histone deacetylase inhibitor approved in China for relapsed PTCL and double-expressor DLBCL (with R-CHOP). It blocks enzymes that lymphoma cells use to silence anti-cancer genes and may help restore CD20 expression (potentially improving rituximab efficacy).

U.S. access: Clinical trials (search “tucidinostat” or “HBI-8000” on ClinicalTrials.gov), compassionate-use applications through HUYABIO International, or treatment in China. Travel to China for treatment is logistically complex; major centers include Peking University Cancer Hospital, Shanghai Ruijin Hospital, and Sun Yat-sen University Cancer Center.

Estimated costs (China treatment): Approximately $3,000–$5,000 per month for the medication, plus travel and lodging.

DDGP for Advanced ENKTL

A Chinese-developed regimen that outperformed the older SMILE protocol. The component drugs (dexamethasone, cisplatin, gemcitabine, pegaspargase) are all available in the U.S. — your team can choose to use this protocol without travel.

Compound Kushen Injection (CKI) — Supportive Care from TCM

CKI is an injectable extract of two Chinese herbs (Sophora flavescens and Smilax glabra), used in Chinese hospitals since 1995 and approved by China’s drug regulator (NMPA) as supportive cancer care.

• Mechanism: Lowers MYC and TERT, slows lymphoma cell growth in laboratory studies.
• Best evidence: Reduces severity of radiation-induced skin damage and chemotherapy-induced mouth sores. Several meta-analyses of randomized Chinese trials support this supportive role.
• Access in the U.S.: Not FDA-approved. Only available in China or via an integrative oncologist with import experience. Use as a supportive layer, not a treatment for the lymphoma itself.

Mogamulizumab (Poteligeo)

FDA-approved for relapsed/refractory CTCL. Standard of care in Japan for ATLL. Available at any U.S. infusion center with insurance approval (typically 2–4 weeks). Caution: If stem-cell transplant is planned, increased graft-versus-host disease risk must be considered.

NK Cell Therapies

Japanese groups have led NK cell therapy research for NHL. Autologous expanded NK cells + rituximab (Tokyo Women’s Medical University, study ID UMIN000014072) and allogeneic haploidentical donor NK cells (NCT00625729) are being studied. NK cell therapy typically has lower toxicity than CAR-T. Many U.S. centers (MD Anderson, City of Hope, MSK) now have CAR-NK trials.

Rapid Rituximab Infusion

Published Japanese trial data demonstrated that rituximab given over 90 minutes at 4 mg/mL concentration (vs. the standard 3–6 hour first infusion) was tolerated safely by 93% of patients. Many U.S. centers now use rapid scheduling starting at cycle 2. If your infusions are long, ask your team about this — it saves hours per cycle.

Kampo Medicine: Juzentaihoto (JTT, TJ-48)

A standardized Japanese herbal prescription studied as supportive care during chemotherapy. Published research suggests it may help preserve immune cell counts and reduce chemotherapy-related immunosuppression.

Access: Available through Japanese suppliers and some integrative-medicine pharmacies. Cost typically $30–$80 per month. Always inform your oncologist, as some herbs may interact with chemotherapy.

Korean oncologists, particularly at Asan Medical Center and Samsung Medical Center (Seoul), are leaders in ENKTL care and ex vivo expanded NK cell therapies for relapsed B-cell NHL. For most U.S. patients, the practical route is a U.S.-based CAR-NK trial, but Korean research provides the scientific foundation for many of these approaches.

Mistletoe extract (Viscum album L.) is the most widely used integrative cancer therapy in Germany, Switzerland, and Austria. Given by subcutaneous injection. Brand names include Iscador, Helixor, AbnobaVISCUM, and Iscucin.

• Published evidence: Reduces fatigue, improves quality of life, and supports immune function during chemotherapy. Some published case reports describe durable remissions in chemo-resistant DLBCL patients who added mistletoe. These are case reports, not randomized trials.
• European access: Anthroposophic clinics such as Klinik Havelhöhe (Berlin; info@havelhoehe.de) and the Lukas Klinik (Switzerland).
• North American access: Not FDA-approved. Available through compounding pharmacies and integrative-oncology clinics. Cost typically $100–$400 per month.
• Cautions: Fever and local skin reactions are expected. Do not start during active aggressive chemotherapy without oncologist approval.

Hyperthermia & Photodynamic Therapy (PDT)

Whole-body hyperthermia (raising body temperature to fever-range under controlled conditions) and locoregional hyperthermia are sometimes offered in Germany as adjuncts to chemotherapy. Evidence in NHL is mostly from small studies. Photodynamic therapy uses a light-activated drug to kill cancer cells in the skin and is used in Germany, Russia, and parts of Eastern Europe for early-stage CTCL lesions. These are reasonable adjuncts for cutaneous disease but should not replace systemic therapy when systemic treatment is needed.

For patients with ATLL, the arsenic + interferon-alpha + AZT combination is one of the most important developments in the field. Developed by the Bazarbachi group (originally Hôpital Necker, Paris; now American University of Beirut).

U.S. access: MD Anderson, the National Cancer Institute, and Memorial Sloan Kettering have run trials. Search ClinicalTrials.gov for “arsenic ATLL” or “interferon zidovudine ATLL.”

Russian oncology centers (especially the Hematology Research Center in Moscow and the Petrov Institute in St. Petersburg) have a long tradition in T-cell and aggressive lymphoma care. Published real-world Russian data emphasize high-dose chemotherapy followed by autologous stem cell transplant for eligible patients with aggressive T- and NK-cell lymphomas.

Practical note: For most North American patients, the practical route is to confirm that your U.S. center is using comparable high-dose protocols. Travel to Russia for treatment is currently impractical for most patients due to political and logistical constraints.

• India: Tata Memorial Centre (Mumbai) and AIIMS (Delhi) run high-volume lymphoma programs and have published on cost-effective adaptations of standard regimens. Some Ayurvedic preparations (curcumin-rich formulas, Withania somnifera/ashwagandha) have preclinical anti-lymphoma data, but human data are limited.
• Israel: Large clinical-trial activity in CAR-T (Sheba Medical Center, Hadassah). Israeli investigators have contributed important real-world CAR-T outcomes data.
• Cuba: Long history of biologics development (interferons, monoclonal antibodies including nimotuzumab). Limited applicability to NHL but worth mentioning for completeness.

Several drugs developed outside the United States have become important treatment options across NHL subtypes. Some are now FDA-approved; others remain available only in their country of origin.

Zanubrutinib (Brukinsa) — China-Originated BTK Inhibitor, Now Global

Developed by BeiGene in Beijing, zanubrutinib is a second-generation Bruton’s tyrosine kinase (BTK) inhibitor designed for greater BTK selectivity and fewer off-target cardiac and bleeding side effects than first-generation ibrutinib. It is now FDA-approved across multiple indications:

• Mantle cell lymphoma (MCL): Accelerated approval for relapsed/refractory MCL after at least one prior therapy.
• Chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL): Full approval based on the ALPINE trial, which demonstrated superior progression-free survival and fewer cardiac adverse events compared to ibrutinib.
• Marginal zone lymphoma (MZL): Accelerated approval for relapsed/refractory MZL after at least one prior anti-CD20 therapy.
• Waldenström macroglobulinemia (WM): Approved for WM, with published data showing high response rates including in patients with MYD88 and CXCR4 mutations.
• Follicular lymphoma (FL): Approved for relapsed/refractory FL after at least two prior lines of therapy.

Practical note: Zanubrutinib is widely available at U.S. oncology practices and covered by most insurance plans. It is now a preferred BTK inhibitor over ibrutinib in many guidelines due to its improved safety profile. No international travel is needed.

Mogamulizumab (Poteligeo) — Japan-Developed Anti-CCR4 Antibody

Developed by Kyowa Kirin and first approved in Japan in 2012 for adult T-cell leukemia/lymphoma (ATLL), mogamulizumab is a humanized monoclonal antibody targeting CCR4, a chemokine receptor expressed on malignant T-cells. It was subsequently FDA-approved for relapsed/refractory mycosis fungoides and Sézary syndrome (the two main forms of cutaneous T-cell lymphoma, CTCL).

• ATLL: In Japan, mogamulizumab is a standard treatment for relapsed or aggressive ATLL. This is directly relevant because the guide covers HTLV-1-driven ATLL, which is endemic in Japan, the Caribbean, and parts of West Africa and South America.
• CTCL (mycosis fungoides and Sézary syndrome): The MAVORIC trial demonstrated superior progression-free survival compared to vorinostat. Published PROCLIPI registry data report improved overall survival in mogamulizumab-treated CTCL patients.
• Transplant caution: Mogamulizumab depletes regulatory T-cells, which increases the risk of severe graft-versus-host disease if allogeneic stem cell transplant is performed afterward. If transplant is being considered, discuss sequencing carefully with your transplant team.

U.S. access: Available at any oncology infusion center with insurance approval (typically 2–4 weeks for prior authorization).

Orelabrutinib — NMPA-Approved BTK Inhibitor (China)

Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare Pharma and approved by China’s National Medical Products Administration (NMPA) for relapsed/refractory CLL/SLL and relapsed/refractory MCL. Published Chinese phase 2 data report overall response rates above 80% in both indications, with a favorable safety profile similar to other second-generation BTK inhibitors.

• Key difference from zanubrutinib: Orelabrutinib is not yet approved outside China. It is relevant as a potential option for patients who have exhausted FDA-approved BTK inhibitors or who are considering treatment in China.
• Clinical trials: Search ClinicalTrials.gov for “orelabrutinib” to check for any active U.S. enrollment.

Relmacabtagene Autoleucel (Relma-cel) — NMPA-Approved CAR-T (China)

Relma-cel is an anti-CD19 CAR T-cell therapy developed by JW Therapeutics (now part of Bioatla/Anke Bio) and approved by China’s NMPA for relapsed/refractory large B-cell lymphoma (primarily DLBCL) after two or more prior lines of therapy. It was the second CAR-T product approved in China.

• Published data: The RELIANCE trial reported an overall response rate of approximately 75% and a complete response rate of approximately 52% in heavily pretreated DLBCL patients. The safety profile was comparable to FDA-approved CAR-T products, with manageable rates of cytokine release syndrome and neurotoxicity.
• Relevance for U.S. patients: Relma-cel is not FDA-approved and is not available in the United States. It is primarily relevant for patients considering CAR-T treatment in China, which some patients have pursued when U.S. CAR-T slots are unavailable or when insurance denials occur. Treatment in China requires careful coordination with a Chinese hematology center and your U.S. oncologist for follow-up care.
• Estimated costs (China): Approximately $120,000–$180,000 USD for the CAR-T product, plus hospitalization, monitoring, and travel costs. This is substantially less than U.S. CAR-T list prices but does not include the logistical complexity of international medical travel during active lymphoma.

A diabetes drug that activates AMPK and lowers insulin/IGF-1 signaling. A small randomized phase 2 trial (Egyptian study) showed higher complete response rates when added to R-CHOP in DLBCL. However, a larger retrospective Mayo Clinic analysis did not replicate the benefit. The evidence is conflicting and not yet definitive — neither study alone is conclusive.

Practical: Discuss with your oncologist. Typical trial doses started at 500 mg extended-release daily, titrated over weeks. Contraindicated in severe kidney disease (CKD stage 4–5) or around IV contrast scans.

Cost: Approximately $5–$15/month generic.

Published pooled analysis of 4 trials (1,467 CLL/SLL patients on ibrutinib) found statin users had ~38% lower mortality (adjusted HR 0.62) and longer PFS (adjusted HR 0.74). The PREVENT trial showed atorvastatin 40 mg daily reduced heart failure risk during anthracycline chemotherapy. A 2024 ASH report linked statin use to improved overall survival in NHL more broadly.

Practical: If you have any cardiovascular reason for a statin (or are receiving anthracyclines), this is a well-supported addition to discuss with your team.

Cost: Generic, very low.

A common antibiotic that also blocks NF-kB and induces apoptosis in some T-cell lines. Published data from IELSG39 and other series show durable responses in ocular adnexal MALT (2-year PFS around 75%).

Risks: Photosensitivity, esophageal irritation. Interactions with iron/calcium/antacids.

An autophagy inhibitor (anti-malarial/arthritis drug). Published preclinical data show HCQ may enhance p53-dependent apoptosis in aggressive B-cell lymphoma models. Clinical trials in other cancers have paired HCQ with chemotherapy.

Risks: Retinal toxicity with prolonged use (baseline and 6-monthly eye exams required), GI side effects, rare cardiac issues. This is not a casual addition — discuss with your team as an experimental consideration.

Active compound in turmeric. Published laboratory data show inhibition of NF-kB and STAT3 pathways central to ABC-DLBCL biology. Use a high-bioavailability formulation (Theracurmin, Meriva, Longvida, or BCM-95 — standard turmeric powder is poorly absorbed).

Cautions: Increases bleeding risk with anticoagulants. Hold for several days around surgery. May interact with chemotherapy timing. Evidence in NHL is preclinical and mechanistic — no large NHL phase 3 trial.

• Celecoxib + metronomic cyclophosphamide: Published phase 2 trial in heavily pretreated aggressive NHL showed safety and responses. Preclinical data suggest celecoxib may sensitize lymphoma cells to CAR-T. Risks include GI bleeding and kidney function decline.
• Aspirin (low-dose): Anti-inflammatory. Limited direct NHL evidence; rationale is reasonable in patients with thrombosis risk. Discuss bleeding risk with your team.
• Itraconazole: Antifungal that inhibits Hedgehog signaling (active in some T-cell lymphomas). Mostly preclinical evidence. Oral, well-tolerated, inexpensive.
• Fenofibrate: Activates PPAR-alpha, which has anti-lymphoma effects in DLBCL preclinical models. Worth considering in patients who already have metabolic syndrome. Evidence is mechanistic, not yet clinical in lymphoma.
• Disulfiram, mebendazole, niclosamide, clarithromycin, artesunate: All older drugs with preclinical anti-lymphoma signals. Use only inside a research framework or under specialist supervision.

Lenalidomide, pomalidomide: These are now core lymphoma drugs (FDA-approved for relapsed follicular and marginal zone lymphoma), not truly “repurposed.”

Whatever else you do, start here. Mediterranean eating is the best-supported dietary pattern across cancers and is considered safe during active NHL treatment.

• 5–9 servings of vegetables and fruit daily
• Olive oil as the main fat
• Fish (especially fatty fish like salmon or sardines) twice a week
• Whole grains, nuts, and legumes
• Limited red meat, minimal processed meat
• No sugary drinks or ultra-processed foods
• Moderate or no alcohol

This is the single highest-yield supplement in NHL based on published data. Multiple studies have linked low vitamin D levels to worse outcomes in DLBCL treated with rituximab-based chemotherapy. The proposed mechanism involves supporting rituximab’s antibody-dependent cellular cytotoxicity (ADCC).

• Test: 25-hydroxyvitamin D
• Target: 40–60 ng/mL (discuss with your team)
• Repletion: If deficient, your doctor may prescribe a loading regimen followed by maintenance dosing
• Monitor: Calcium levels. Do not megadose without testing — excessive levels can cause hypercalcemia
• Cost: Generic, very inexpensive

A ketogenic diet produces ketone bodies, especially beta-hydroxybutyrate (BHB), which published research shows may serve as fuel for CAR T-cells (see Immunotherapy section).

Cautions:

• Do NOT use if you are losing weight you cannot afford to lose (cachexia risk)
• Published preclinical work suggests ketogenic conditions may impair NK cell survival in some settings — may not be compatible with NK-based therapies
• Not appropriate during tumor lysis risk (Burkitt, high-burden DLBCL)
• Always work with an oncology dietitian. Monitor weight, electrolytes, kidney function, and ketone levels

Fasting-mimicking diet (FMD): A 5-day plant-based low-calorie protocol. Published human data in solid tumors (DIRECT trial in breast cancer) showed reduced toxicity and improved tumor response. A CLL pilot showed feasibility. Do NOT use if underweight, cachectic, or at tumor lysis risk. Commercial kit: ProLon (~$250 per cycle).

Time-restricted eating (TRE): 16 hours fasting, 8 hours eating. Gentler than full FMD. Early-phase studies are exploring intermittent fasting and time-restricted eating in CLL/SLL, but the evidence remains preliminary. Discuss with your hematologist before trying.

• Protein: Aim for 1.2–1.5 g/kg/day during active treatment if kidney function allows. Protects muscle mass (sarcopenia is a strong predictor of poor chemo tolerance).
• Exercise: Walking 30 minutes most days plus gentle resistance training 2–3 times/week. Published data show this improves chemotherapy completion, reduces fatigue, and may improve survival in DLBCL. Consult your team for safe, individualized thresholds.
• Sleep: Aim for 7–8 hours. Poor sleep increases inflammatory markers.
• Mind-body: Mindfulness-based stress reduction (MBSR), cognitive behavioral therapy, yoga, and support groups have published evidence for fatigue, anxiety, and quality of life.

CAR-T means “chimeric antigen receptor T-cell.” The patient’s own T-cells are collected, genetically engineered to recognize a specific marker on the lymphoma (usually CD19), expanded, and re-infused.

FDA-approved CAR-T products for NHL:

• Axicabtagene ciloleucel (Yescarta) — DLBCL after first-line failure (ZUMA-7), DLBCL in 3rd line, follicular lymphoma in 3rd line (ZUMA-5)
• Lisocabtagene maraleucel (Breyanzi) — DLBCL, follicular, mantle cell, CLL
• Tisagenlecleucel (Kymriah) — DLBCL in 3rd line
• Brexucabtagene autoleucel (Tecartus) — Mantle cell lymphoma

ZUMA-5 long-term data are particularly notable: at median follow-up of 5.4 years in relapsed/refractory indolent NHL (mostly follicular), overall response was 90%, complete response 75%, and very few patients relapsed beyond 2 years.

Side effects (managed by experienced teams): Cytokine release syndrome (CRS) — treated with tocilizumab; neurotoxicity (ICANS) — treated with steroids; long-term low immunoglobulin levels — manageable with IVIG.

Estimated cost: CAR-T list prices range from ~$373,000 to ~$475,000 per treatment. Most insurance plans cover it when medically indicated. Hospital fees and monitoring add to total cost. Financial assistance is available through manufacturer programs and the LLS.

A published 2026 study demonstrated that beta-hydroxybutyrate (BHB) is preferentially used by activated CAR T-cells as fuel, feeding the mitochondrial citric acid cycle and acting as an epigenetic signal that enhances CAR-T persistence and reduces exhaustion.

This is being tested in a phase 1 trial at the Abramson Cancer Center, University of Pennsylvania (NCT06610344). Patients with large B-cell NHL scheduled for standard-of-care anti-CD19 CAR-T receive an oral BHB supplement starting one day after lymphodepleting chemotherapy and continuing for 28 days after CAR-T infusion.

How to act on this: If you are heading for CAR-T, ask whether the Penn trial is enrolling. Even if not eligible, discuss with your oncologist whether modified ketogenic timing during the CAR-T window makes sense. This is off-label and experimental.

Additionally, a small published study of BTK inhibitor maintenance after CAR-T in MCD-subtype DLBCL (N=12) reported 2-year PFS of 89% — worth discussing if you have MCD-type DLBCL going to CAR-T.

Bispecifics are engineered antibodies with two arms — one grabs the lymphoma cell (usually CD20), one grabs a T-cell (CD3). They force T-cells to attack lymphoma without genetic engineering.

• Epcoritamab (Epkinly) — Subcutaneous, FDA-approved for relapsed/refractory DLBCL
• Glofitamab (Columvi) — IV, FDA-approved for relapsed/refractory DLBCL
• Mosunetuzumab (Lunsumio) — FDA-approved for relapsed follicular lymphoma

These are especially useful for patients who cannot access a CAR-T center, who have disease progression after CAR-T, or whose disease is moving too fast to wait for CAR-T manufacturing.

FDA accelerated approval May 13, 2026 for relapsed/refractory MCL after ≥2 prior treatments including a BTK inhibitor. Next-generation BCL-2 inhibitor (more potent and selective than venetoclax in published laboratory studies).

Pivotal trial (BGB-11417-201): 52% overall response in heavily pretreated post-BTK MCL, median time to response 1.9 months, median duration of response 15.8 months.

If you have post-BTKi MCL, this is the most important new option to discuss with your oncologist.

• Polatuzumab vedotin (Polivy) — Anti-CD79b ADC, in Pola-R-CHP for higher-risk DLBCL and in salvage
• Tafasitamab (Monjuvi) — Anti-CD19 antibody, with lenalidomide in relapsed DLBCL
• Loncastuximab tesirine (Zynlonta) — Anti-CD19 ADC in 3rd-line DLBCL
• Tazemetostat (Tazverik) — EZH2 inhibitor for EZH2-mutated relapsed follicular lymphoma
• Pirtobrutinib (Jaypirca) — Non-covalent BTK inhibitor for MCL and CLL after covalent BTKi progression
• Brentuximab vedotin (Adcetris) — Anti-CD30 ADC for CD30-positive PTCL, ALCL, CTCL

Still important for several scenarios:

• First-remission autologous SCT for MCL in fit younger patients (under 65)
• Autologous SCT for relapsed DLBCL that responds to salvage chemotherapy (though CAR-T is often chosen first now)
• Autologous SCT consolidation for relapsed FL after CR2
• Allogeneic SCT for relapsed T-cell lymphomas, ATLL, and selected high-risk B-cell relapses. HLA typing should be discussed early.

Foundational and Standard Care

• Second pathology opinion at a high-volume lymphoma center
• Complete molecular workup: NGS panel, FISH, cell-of-origin, CD30, EBV, and subtype-specific markers
• Infection screen: HIV, HBV, HCV, EBV, HTLV-1, H. pylori, C. psittaci as appropriate
• Baseline echocardiogram, labs (CBC, metabolic panel, LDH, beta-2 microglobulin, uric acid), PET/CT with MTV
• Fertility preservation if pre-menopausal or under 45
• Confirm treatment regimen matches NCCN guidelines for your exact subtype and risk
• Treat any identified infectious driver first (or in parallel)

Immediate Supportive Layer

• Test vitamin D — begin repletion if low
• Begin Mediterranean dietary pattern
• Start daily walking and light resistance training
• Stop St. John’s Wort and other strong CYP3A4 inducers
• Discuss metformin and statin addition with your oncologist as appropriate
• Register with LRF Helpline (800-500-9976) and LLS (800-955-4572)

Set Up for What’s Next

• HLA typing if transplant might be needed
• Tissue banking — ask pathology to retain extra biopsy material
• Identify 2–3 clinical trials matching your subtype as contingencies

Standard Care, On Time, Full Dose

Do not allow dose reductions or delays unless medically required. Use growth factor support, anti-nausea medications, neuropathy monitoring, and nutrition to stay on schedule.

Layer the Right Adjuncts

• Continue vitamin D, Mediterranean diet, exercise, mind-body approaches
• Continue metformin if started and tolerated
• If indolent or supportive setting and weight-stable, consider time-restricted eating (16/8) with dietitian supervision
• If aggressive disease with high tumor burden or weight loss, focus on protein and calories — do not restrict

Subtype-Specific Layering (Discuss with Your Team)

• Double-expressor DLBCL: Ask about tucidinostat access through a trial
• PTCL: Ask about tucidinostat access
• CTCL: Ask about mogamulizumab (Poteligeo) — FDA-approved
• Ocular MALT: Doxycycline as first-line
• ATLL: Ask about arsenic + interferon + AZT
• Advanced ENKTL: Ask about DDGP regimen
• CAR-T candidate: Explore the Penn BHB trial (NCT06610344)

Monitor

• Interim PET/CT after cycle 3 or 4 (Deauville score: 1–3 = continue plan; 4–5 = consider biopsy and treatment change)
• ctDNA / MRD tracking if available
• Labs every cycle. Weight, muscle mass, neuropathy, mood, sleep

If Complete Remission

• Transition to surveillance. ctDNA may be used for sensitive relapse detection.
• Maintenance: rituximab for FL and MCL where indicated. Discuss continuing metformin in DLBCL.
• Continue lifestyle layers indefinitely: vitamin D, Mediterranean eating, exercise, mind-body, sleep
• Survivorship clinic for late-effects monitoring (heart, thyroid, second cancers, bone density, fertility, mental health)

If Partial Response or Relapse

• Re-biopsy with full molecular re-profiling. Disease can transform (e.g., FL to DLBCL) or develop new targetable mutations.
• CAR-T (preferred early after relapse for DLBCL)
• Bispecifics (epcoritamab, glofitamab, mosunetuzumab)
• Subtype-specific: sonrotoclax for post-BTKi MCL; tazemetostat for EZH2-mutated FL; pirtobrutinib for BTKi-resistant MCL/CLL; loncastuximab for 3rd-line DLBCL
• Allogeneic SCT for T-cell or aggressive relapsed B-cell disease with a donor
• Re-engage international options: tucidinostat, mogamulizumab, arsenic protocol for ATLL, DDGP for ENKTL
• Trial search: ClinicalTrials.gov for your exact subtype

For men: Sperm banking (cryopreservation) can be completed in 1–2 days at any fertility clinic, before chemotherapy begins. Even if sperm count appears low because the lymphoma has temporarily suppressed production, banking is still worthwhile — stored samples from before treatment are your best insurance. Samples can be stored for decades. Most insurance covers fertility preservation linked to a cancer diagnosis.

For women: Egg (oocyte) or embryo freezing is the most reliable option. It requires 10–14 days of hormone injections to stimulate the ovaries, followed by a minor egg retrieval procedure. This is usually feasible even before starting treatment if diagnosis allows a brief delay. Oncofertility specialists at Huntsman Cancer Institute (801-587-7000) can coordinate quickly around a cancer timeline. UCSF and MSK also maintain dedicated oncofertility programs with rapid intake.

Ovarian protection injections (GnRH agonist): A monthly injection called leuprolide (Lupron) can partially protect ovarian function during chemotherapy by putting the ovaries in a temporary “sleep” state. This is not as reliable as embryo banking but is a useful option when there is no time for egg retrieval. It can be started at the same time as chemotherapy.

How gonadotoxic is the regimen? Cyclophosphamide (in R-CHOP) is the main fertility risk. It can permanently reduce egg supply and cause early menopause in some women, especially those over 35. Bendamustine (in BR) also affects both male and female fertility. Rituximab alone does not cause infertility. Your oncologist can estimate your individual risk based on your regimen, planned total dose, and age.

Questions to Ask Before Treatment Starts

• How likely is this regimen to affect my fertility permanently?
• Can we delay 2 weeks to bank eggs or sperm?
• Can you refer me to an oncofertility specialist today?
• Is a GnRH agonist (Lupron) appropriate for me during chemotherapy?
• Does my insurance cover fertility preservation for cancer patients?

All NHL drugs — including rituximab, cyclophosphamide, and newer targeted agents like ibrutinib — can cause birth defects or miscarriage if pregnancy occurs during treatment. Effective contraception is required for all patients of reproductive age during treatment, both male and female.

Men taking ibrutinib (Imbruvica) are required to use a condom during sex because the drug is present in semen. Hormonal contraception (pill, patch, injection, ring) is safe to use alongside most NHL treatments. An IUD is also appropriate and highly reliable. Continue contraception throughout all active treatment and for at least 6 months after the last chemotherapy dose — or 12 months after the last rituximab dose.

If you are already pregnant at diagnosis, a specialized team must be involved right away. Many NHL treatments can be given safely in the second and third trimester. First-trimester treatment carries higher risk and requires an urgent, individualized discussion between your oncologist, a high-risk obstetrician, and you.

When is it safe to try? Most oncologists recommend waiting at least 12 months after completing chemotherapy before trying to conceive. This allows any damaged eggs or sperm to clear, gives the lymphoma time to declare itself (most relapses happen within the first 2 years after treatment), and confirms that you are in stable remission.

Does pregnancy increase the risk of relapse? No. Large international registries show that women who conceive after curative NHL treatment do not have worse lymphoma outcomes than those who do not. You can pursue pregnancy without it posing a medical risk to your lymphoma, once you are in remission and past the highest-risk window for relapse.

Monitoring during pregnancy: Your lymphoma team should stay involved throughout any pregnancy after NHL. Routine CT scans are avoided during pregnancy, but MRI (without gadolinium in the first trimester) and ultrasound can be used to assess lymph nodes if there is clinical concern. Coordinate care between your oncologist and a maternal-fetal medicine specialist.

Breastfeeding: If you are on rituximab maintenance therapy, breastfeeding is not recommended because rituximab passes into breast milk and could deplete your baby’s B cells (immune cells). Once maintenance is complete and rituximab has cleared from your body (typically 12 months after the last dose), breastfeeding is generally safe.

• Fever of 100.4°F (38°C) or higher during or within weeks of chemotherapy. Low white-cell counts plus fever (neutropenic fever) is a medical emergency. Go to the ER if you cannot reach your team quickly.
• Shaking chills, fast heartbeat, confusion, or a drop in blood pressure — possible serious infection or sepsis.
• Sudden shortness of breath, chest pain, or swelling and pain in one leg — possible blood clot, which is more common in lymphoma.
• New confusion, severe headache, one-sided weakness, slurred speech, or a seizure — possible CNS involvement, or after CAR-T/bispecific, possible neurotoxicity (ICANS).
• During or right after CAR-T or a bispecific antibody: fever, low blood pressure, or trouble breathing — possible cytokine release syndrome (CRS). Your team will have given you a wallet card; show it at any ER.

• New or rapidly enlarging lumps (lymph nodes) anywhere — neck, armpit, groin
• Drenching night sweats, unexplained fevers, or unexplained weight loss (“B symptoms” that can signal progression)
• Severe or persistent vomiting or diarrhea that stops you keeping fluids down
• New, severe bone pain or pain that wakes you at night
• Yellowing of skin or eyes, or dark urine — possible liver problem or hepatitis B reactivation (especially if HBV-positive and on rituximab)
• A scan or blood test (like a rising LDH) that worries you — ask the team to explain what it means and whether it changes the plan

• Numbness or tingling in fingers and toes (chemotherapy neuropathy, often from vincristine) — early reporting can prevent permanent damage through dose adjustment
• Steroid side effects that are hard to manage — mood swings, sleeplessness, high blood sugar
• Ongoing fatigue, low mood, or anxiety — these are treatable and should not be tolerated silently
• Any supplement, diet, or repurposed drug you are considering — before you start it, not after
• A feeling that the team is not listening or communicating well — this is a valid reason to request a second opinion

• Interim PET shows Deauville 4 or 5 (inadequate response) — ask about biopsy, molecular re-testing, and changing treatment
• Disease comes back (relapse) — re-biopsy, full molecular re-profiling, and a discussion of CAR-T, bispecifics, and trials should happen quickly
• You are told “there is nothing more to do” — this is the moment to get a second opinion at a high-volume center, which may know of trials your local team does not
• Your subtype is rare (PTCL, ENKTL, ATLL, MCL, PCNSL) — these benefit most from specialist centers, ideally from the start

1. Localized disease + targeted local treatment: Published case of primary lacrimal sac DLBCL treated with local radiotherapy alone — 21-year disease-free survival.
2. Driver infection treated, lymphoma resolves: Gastric MALT cured by H. pylori antibiotics. Ocular MALT controlled 14+ years on doxycycline. Splenic MZL regressed after HCV was cleared.
3. Multi-drug, full-dose, on-time first-line therapy: Published long-term data suggest roughly 42% of follicular lymphoma patients on standard chemoimmunotherapy achieved what appears to be cure. The strongest predictor was getting the full planned dose on schedule.
4. Genetic-subtype-guided escalation: The Shanghai Protocol trials showed dramatically higher complete response rates when the added drug was matched to the lymphoma’s genetic subtype.
5. BCL-2 + BTK inhibition in MCL: AIM trial 7-year data — MRD-negative patients went off all therapy and stayed in remission for years.
6. CAR-T in indolent NHL: ZUMA-5 at 5+ years — very few patients relapsed beyond 2 years, data beginning to suggest curative potential in some relapsed/refractory FL patients.
7. BTK inhibitor maintenance after CAR-T in MCD-subtype DLBCL: Small study (N=12) but 2-year PFS of 89% with no observed relapses.
8. Mistletoe + chemoimmunotherapy in chemo-resistant DLBCL: Published case reports of long-term survival — not standard, but the case literature exists.
9. Arsenic + IFN + AZT in ATLL: Chronic and smoldering ATLL patients living 5+ years on this virus-targeted approach.
10. Patient at a high-volume lymphoma center: Across every subtype, the strongest modifiable predictor of long-term survival is being treated at a center with a dedicated lymphoma team.

• Share the load on purpose. Make a written list of jobs — driving to appointments, prescriptions, meals, childcare, insurance calls, note-taking — and assign them. Friends who ask “how can I help?” want a specific task. Give them one.
• Use a coordination tool. Free services like CaringBridge (for updates) and Lotsa Helping Hands or a shared calendar (for scheduling meals and rides) reduce the mental load enormously.
• Protect your own health. Keep your own medical appointments. Sleep. Eat. Move your body. Caregiver exhaustion is real and not a sign of weakness.
• Accept imperfection. You will forget things, lose patience, and have bad days. That is normal. The goal is steady presence, not perfection.

• Bring two people when possible: one to listen and ask questions, one to take notes
• Ask permission to record the conversation on a phone. Most clinics allow it. Appointments produce more information than anyone remembers.
• Bring a written list of questions, most important first. Hand a copy to the doctor at the start.
• Keep one binder or one digital folder with all records: pathology reports, scan reports, lab results, medication list, contact numbers, insurance information. Bring it to every visit.
• Before leaving, ask: “What are we watching for before the next visit? What would make us call you sooner?”

Distress, fear, anger, and grief are normal responses — for the patient and the family. They are not weakness and not something to hide from the medical team.

• Most cancer centers have social workers, psychologists, and psychiatrists who specialize in cancer. Ask for a referral. This is standard supportive care.
• Anxiety and depression are common and treatable. Counseling and medication (when appropriate) both help. Tell the team.
• Support groups — through LRF, LLS, or CancerCare — connect you with others who understand.
• Mind-body practices (mindfulness, gentle yoga, breathing exercises, prayer or meditation) have published evidence for reducing anxiety and fatigue.

Honesty in age-appropriate language is almost always better than silence. Children sense when something is wrong, and what they imagine is often worse than the truth.

• Use simple, true words. It is okay to say “cancer” and to name the treatment.
• Reassure them about daily life — who will take them to school, who will be home — because that is what younger children worry about most.
• Many cancer centers have child-life specialists or family counselors who can help guide these conversations.

• Ask the cancer center for a financial counselor or navigator early — not after bills pile up
• Keep a simple log of medical expenses and mileage; some are tax-deductible
• Ask the employer’s HR about medical leave (FMLA in the U.S.) and short-/long-term disability coverage
• Consider getting basic legal documents in order early — a medical power of attorney and an advance directive. This is responsible planning for any serious illness, not a prediction.

• What is my exact lymphoma subtype, and how confident are you in that diagnosis?
• Is my lymphoma indolent (slow) or aggressive (fast)? How urgently do we need to start treatment?
• Will you order a full NGS molecular panel, FISH for MYC/BCL2/BCL6, and cell-of-origin testing? Will the results change my treatment?
• Have we screened for infections that can drive lymphoma — H. pylori, hepatitis B and C, HIV, EBV, HTLV-1, Chlamydia psittaci?
• Should I get a second-opinion pathology review at a high-volume lymphoma center?
• What is the proposed treatment, and does it match current NCCN guidelines for my subtype and risk level?
• What is the realistic goal — cure, or long-term control?
• Do I need a baseline heart test before treatment? Should we discuss fertility preservation?
• Are there clinical trials I should consider now, before treatment locks in?

• What is the name of my exact regimen, how many cycles, and how far apart?
• For higher-risk DLBCL: should we use Pola-R-CHP rather than R-CHOP? For double-hit: should we use DA-EPOCH-R?
• What side effects are most likely, and what will we do to prevent or manage them?
• Do I need a port placed? Do I need preventive antibiotics or antivirals?
• What supplements or medications should I stop before treatment?
• Can I take vitamin D, and should I be tested first?
• Is there any reason metformin would not be safe for me to discuss adding?
• Who do I call after hours, and what symptoms should make me call?

• How is the treatment working so far? When is the next response scan?
• Are my blood counts where they should be? Do we need growth-factor support?
• I am having [specific side effect] — what can we do about it?
• Are we still on schedule and on full dose? If not, why, and what does that mean?
• Is it safe to start [a specific supplement or repurposed drug] now? Are there interactions?
• Should we be tracking ctDNA or MRD?

• Do you agree with the diagnosis and the molecular interpretation?
• Would you recommend the same treatment plan? If not, what would you change and why?
• What clinical trials at your center would fit my subtype?
• Are there international protocols (Chinese, Japanese, or other) relevant to my subtype?
• If this treatment does not work, what would the next steps be?

• Do we need a new biopsy and new molecular testing? Has the disease transformed?
• Am I a candidate for CAR-T? For a bispecific antibody? For a transplant?
• What clinical trials should we consider now?
• Are there international or compassionate-use options for my subtype?
• What is the realistic goal now, and what are the trade-offs of each option?

• Given everything you know about my case, what is the realistic range of outcomes?
• Beyond the treatment itself, what have you seen actually help patients do well?
• What is the most useful thing my family can do to support me?
• How will we know if it is time to shift the focus of care?
• Is there anything I should be asking that I have not?

FAILED The phase 3 PHOENIX trial (NCT01855750) added ibrutinib to R-CHOP for newly diagnosed non-GCB DLBCL. The trial did not meet its primary endpoint of improved event-free survival. In patients under 60, there was a trend toward benefit, but in patients 60 and older, ibrutinib + R-CHOP was associated with increased toxicity and inferior outcomes. Ibrutinib is not recommended as an addition to R-CHOP for untreated DLBCL.

FAILED The phase 3 REMoDL-B trial (NCT01324596) added the proteasome inhibitor bortezomib to R-CHOP for newly diagnosed DLBCL, hypothesizing benefit in the ABC/non-GCB subtype. The trial showed no improvement in progression-free survival or overall survival in any subgroup, including ABC-type DLBCL. Bortezomib is not recommended as an addition to R-CHOP for untreated DLBCL.

FAILED The phase 3 ROBUST trial (NCT02285062) added lenalidomide to R-CHOP specifically for ABC-type DLBCL. Despite strong preclinical rationale and promising phase 2 data, the trial did not meet its primary endpoint of improved progression-free survival. Lenalidomide remains useful in relapsed follicular and marginal zone lymphoma but is not recommended as a first-line addition to R-CHOP for DLBCL.

FAILED The phase 3 GOYA trial (NCT01287741) tested whether obinutuzumab (a next-generation anti-CD20 antibody) was superior to rituximab when combined with CHOP for newly diagnosed DLBCL. Obinutuzumab-CHOP did not improve progression-free survival over R-CHOP and had higher infusion-related toxicity. Rituximab remains the standard anti-CD20 antibody for DLBCL. Obinutuzumab is used in follicular lymphoma and CLL, where it has shown benefit.

FAILED Everolimus (Afinitor), an mTOR inhibitor, was studied in lymphoma but never approved for it. The phase 3 PILLAR-2 trial (NCT00790036), which tested everolimus as maintenance therapy after R-CHOP in high-risk diffuse large B-cell lymphoma, failed to demonstrate a statistically significant improvement in disease-free survival. The drug showed limited single-agent activity in aggressive B-cell lymphomas and significant immunosuppression. mTOR inhibitors are no longer considered a viable monotherapy approach for most NHL subtypes.

DE-ADOPTED Idelalisib (a PI3K-delta inhibitor) was FDA-approved for relapsed follicular lymphoma and CLL. However, multiple clinical trials were halted after reports of excess deaths from opportunistic infections (Pneumocystis jirovecii pneumonia, CMV reactivation) and severe hepatotoxicity, particularly when combined with immunochemotherapy in treatment-naïve patients. The drug is still available but now carries black box warnings and is restricted to heavily pretreated patients. Second-generation PI3K inhibitors (duvelisib, copanlisib, umbralisib) have also faced safety-related market withdrawals. BTK inhibitors and other agents have largely replaced PI3K inhibitors in practice.

WITHDRAWN Umbralisib (Ukoniq), a dual PI3K-delta/CK1-epsilon inhibitor, received accelerated FDA approval in February 2021 for relapsed/refractory marginal zone lymphoma and follicular lymphoma. It was voluntarily withdrawn from the U.S. market in April 2022 after an updated safety analysis revealed an increased risk of death compared to control arms in ongoing trials. This withdrawal was part of a broader reassessment of the PI3K inhibitor drug class. Patients currently on umbralisib should discuss alternatives with their oncologist.

• “Pola-R-CHP DLBCL POLARIX”
• “sonrotoclax mantle cell lymphoma BGB-11417-201”
• “ZUMA-5 follicular lymphoma 5-year follow-up”
• “ZUMA-7 axicabtagene second line”
• “AIM trial ibrutinib venetoclax mantle cell 7-year”

• “GUIDANCE-01 R-CHOP-X DLBCL genetic subtype”
• “GUIDANCE-06 R-ICE-X relapsed DLBCL”
• “chidamide tucidinostat DEB trial double-expressor DLBCL NCT04231448”
• “chidamide R-CHOP elderly DLBCL NCT07493148”
• “DDGP versus SMILE ENKTL NCT01501149”
• “chidamide sintilimab NK/T-cell lymphoma SCENT”

• “beta-hydroxybutyrate BHB CAR-T cell lymphoma”
• “ketogenic diet CAR-T DLBCL NCT06610344”
• “HVMN Ketone-IQ CAR-T trial Penn lymphoma”
• “fasting-mimicking diet ProLon lymphoma DIRECT”
• “time-restricted eating CLL/SLL clinical trial”

• “metformin R-CHOP DLBCL phase 2 randomized”
• “statin ibrutinib CLL pooled analysis”
• “atorvastatin anthracycline cardioprotection PREVENT”
• “doxycycline ocular adnexal MALT IELSG39”
• “curcumin DLBCL NF-kB”
• “celecoxib metronomic cyclophosphamide NHL phase 2”
• “itraconazole hedgehog T-cell lymphoma”
• “fenofibrate PPAR-alpha DLBCL preclinical”
• “Polyphenon E EGCG CLL phase 2 Mayo Clinic”
• “epigallocatechin gallate chronic lymphocytic leukemia apoptosis”

• “Iscador Helixor non-Hodgkin lymphoma”
• “Viscum album DLBCL case report long-term”
• “Compound Kushen Injection radiation dermatitis lymphoma”
• “arsenic interferon zidovudine ATLL Bazarbachi”
• “chronic ATLL arsenic AZT phase 2”
• “mogamulizumab ATLL”
• “mogamulizumab MAVORIC CTCL”
• “mogamulizumab PROCLIPI overall survival”

• “autologous NK cell expansion rituximab UMIN000014072 Tokyo Women’s”
• “haploidentical NK cells NHL NCT00625729”
• “rapid rituximab infusion 90 minutes 4 mg/mL JapicCTI-173663”
• “Juzentaihoto TJ-48 chemotherapy support”

• Single-agent checkpoint inhibitors for most B-cell NHL. PD-1 drugs like pembrolizumab and nivolumab, used alone, have not improved survival in most DLBCL or FL. They have real roles in specific situations (primary mediastinal B-cell lymphoma, ENKTL, classic Hodgkin, post-CAR-T in selected patients) — but not as a general add-on.
• High-dose intravenous vitamin C as a cancer treatment. Despite heavy marketing, IV vitamin C has not been shown to treat lymphoma. It should never replace or delay standard care, and it can interfere with some lab tests and is unsafe in G6PD deficiency.
• “Detox” programs, alkaline diets, and miracle-cure protocols. Baking soda, hydrogen peroxide, extreme cleanses, and similar approaches have no evidence in lymphoma. Time and money spent on them is time and money not spent on what works.

• Foreign “stem cell” clinics. Unregulated stem cell injections for cancer have no scientific basis in NHL. This is completely different from a legitimate stem cell transplant at an accredited center.
• Stacking many herbal supplements during chemotherapy. Documented cases of serious liver toxicity from combining chemotherapy with multiple herbal preparations. One or two well-chosen, evidence-supported items discussed with your team is reasonable. A self-assembled stack of a dozen poorly characterized supplements is dangerous.
• Replacing or delaying standard care for an unproven alternative. This is the single most harmful decision a family can make, especially for aggressive subtypes where weeks matter. Layer adjuncts on top of standard care. Never substitute them for it.
• Stopping prescribed medication on your own. Including steroids, antivirals, or antibiotics. Some prevent life-threatening complications (hepatitis B reactivation, infections). Any change goes through your team.

• Cannabis / CBD. Reasonable for nausea, appetite, pain, and sleep in selected patients. It is not a cancer treatment. It interacts with some drugs through the liver (CYP enzymes) — tell your team and pharmacist.
• Ketogenic and fasting diets. Promising in specific, supervised situations (see the diet section). Harmful if they cause weight loss in someone who cannot afford it, or if used in high-tumor-burden disease with tumor lysis risk.
• Repurposed drugs (metformin, statins, doxycycline, others). Several have real supporting evidence and are reasonable to discuss. But “repurposed and cheap” does not mean “free of risk.” They are layers, added with your team, not substitutes.

• The cancer center’s own financial counseling team — ask at the first visit
• Drug manufacturer patient-assistance programs — every major lymphoma drug has one; search the drug’s official website
• Copay assistance: PAN Foundation, HealthWell Foundation, Patient Advocate Foundation, LLS Co-Pay Assistance Program
• CancerCare (800-813-4673) — financial help and counseling
• Travel and lodging: American Cancer Society Hope Lodge, LLS Travel Assistance, Mercy Medical Angels, Air Charity Network
• For trials: ask the coordinator in writing what the sponsor covers and what your insurance is billed for

Best combination of safety, plausible mechanism, and at least some lymphoma-relevant evidence.

• Vitamin D3. Test 25-hydroxyvitamin D first. Common repletion if low: 50,000 IU weekly for 6–8 weeks, then 2,000–4,000 IU/day. Target 40–60 ng/mL. Take with a fat-containing meal. Recheck after about 3 months.
• Omega-3 (EPA/DHA) fish oil. 1–2 grams combined EPA + DHA per day with food. Anti-inflammatory; supports mood. Note mild blood-thinning effect — tell your team before procedures.
• Mediterranean dietary pattern. Not a supplement, but the foundation. Start immediately.

• Metformin (prescription). 500 mg extended-release daily, titrated toward 1,000–2,000 mg/day with food. Requires adequate kidney function.
• High-bioavailability curcumin. 1–4 g/day (Theracurmin, Meriva, Longvida, BCM-95). Hold around procedures; avoid with anticoagulants unless cleared. May interact with chemotherapy timing.
• Probiotics / fermented foods. May support gut health during chemotherapy. Use caution if severely immunosuppressed or neutropenic.

• Juzentaihoto (TJ-48, Kampo). About 7.5 g/day in studies, used for chemotherapy support. Buy from a reputable importer.
• Astragalus (Huang Qi). Component of several traditional formulas. Modest evidence. Discuss before use, especially with immunotherapy.
• MCT oil. Used to raise ketone levels alongside a ketogenic approach. Start with a teaspoon to avoid stomach upset.
• Melatonin. 3–10 mg at bedtime for sleep. Generally safe; mild evidence for supportive benefit in cancer.

• Take oral targeted cancer drugs exactly as instructed — some require an empty stomach, some require food
• Separate iron and calcium supplements from other medications by at least 2 hours
• Add one new supplement at a time, a couple of weeks apart, so any side effect can be traced
• Around any chemotherapy infusion, follow your team’s guidance on which supplements to hold. Many antioxidants are paused on infusion days as a precaution.
• Before any surgery or biopsy, tell the team about every supplement; several increase bleeding risk

1. Tell every provider about every supplement and over-the-counter product, every time. “Natural” does not mean “no interactions.”
2. The CYP3A4 rule: While on a BTK inhibitor, venetoclax, or sonrotoclax, avoid grapefruit, Seville oranges, St. John’s Wort, and strong antifungals unless your team has specifically planned for it.
3. Space mineral supplements (iron, calcium) at least 2 hours from medications.
4. Watch for stacking: bleeding-risk stacking (fish oil + curcumin + ginkgo + vitamin E + anticoagulant) and sedation stacking (melatonin + magnesium + cannabis + sleep medication).
5. Add one new thing at a time so a side effect can be traced to its cause.

The large majority of NHL is sporadic — it appears in people with no family history, caused by random genetic damage that accumulates with age. NHL is not passed down the way some single-gene diseases are.

Having a first-degree relative (parent, sibling, child) with NHL or another blood cancer modestly raises a person’s own risk. The increase is real but the absolute risk for any individual relative remains low. The pattern is strongest for CLL/SLL, where first-degree relatives have a noticeably higher relative risk, though still a low absolute risk.

• Several blood cancers across close relatives and across generations
• Blood cancers appearing at unusually young ages
• A known inherited immune-deficiency syndrome in the family
• Other cancers clustering in a notable pattern

If any of these fit your family, ask the oncologist for a referral to a genetic counselor — not an internet test.

• Treat known infections linked to lymphoma. Getting hepatitis C cured lowers lymphoma risk. H. pylori, HIV, and HBV should be diagnosed and managed.
• Keep routine medical care. No general screening test for NHL exists, but a primary-care relationship means new lumps, persistent fevers, night sweats, or weight loss get evaluated promptly.
• Know the warning signs. Painless swollen lymph nodes persisting for weeks, drenching night sweats, unexplained fevers, unexplained weight loss, persistent fatigue. Most of the time these are not cancer — but they should be checked.
• Healthy basics. Not smoking, Mediterranean-style diet, healthy weight, limiting alcohol. Modest immune health and overall cancer risk benefits.
• Avoid panic and unnecessary testing. A modest increase over a low baseline is still a low risk. Most relatives of NHL patients never develop lymphoma.

Can NHL be detected before symptoms appear?

No routine screening test for NHL exists. Unlike diabetes (where prediabetes is detectable years ahead), Parkinson’s (where prodromal signs appear a decade before diagnosis), or stroke (where risk factors are modifiable for decades), there is no blood test or imaging study recommended for healthy people to screen for lymphoma.

However, two exceptions are worth knowing about:

• Monoclonal B-cell lymphocytosis (MBL): A precursor state to CLL/SLL, found incidentally on blood tests in roughly 5% of adults over 60. Only about 1–2% of people with MBL per year progress to CLL requiring treatment. If MBL is found, it means regular blood count monitoring — not immediate treatment. For families with multiple CLL cases, this is a discussion worth having with a hematologist.
• Infection-linked lymphomas: Treating the underlying infection before lymphoma develops is genuine prevention. Curing hepatitis C (HCV) reduces the risk of splenic marginal zone lymphoma. Eradicating H. pylori prevents gastric MALT lymphoma. These infections are detectable with simple, inexpensive tests. Family members of people with infection-associated NHL should ask their doctor about testing.

How much earlier does awareness matter?

The honest answer for NHL is not about years of lead time — it is about speed of diagnosis once symptoms appear. Studies consistently show that patients diagnosed at earlier stages do better, and that patients who reach a high-volume lymphoma center faster have better outcomes. The practical benefit of family awareness is:

What family members should not do

Do not pursue whole-body PET scans, CT surveillance, or lymph node biopsies in the absence of symptoms. The false-positive rate is high, the anxiety is real, and the absolute risk for any individual family member remains low. The right approach is awareness without anxiety: know the warning signs, maintain routine healthcare, treat relevant infections, and see a doctor if something persists for more than 2–3 weeks.